UTHR
United Therapeutics Corporation · Healthcare · Biotechnology
动量输入（同类管理人）： 持有人广度 0.0% · 股份流向 -2.9% · 净新建仓位 -4.8% · 公式
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 86.02K | $43.82M | n/a | −2 |
| Q2 2026 | 157 | +4 | 27.98M | $15.17B | +8 | −5 |
| Q1 2026 | 157 | -1 | 29.64M | $17.54B | +5 | −7 |
| Q4 2025 | 157 | +1 | 32.29M | $15.72B | +2 | n/a |
| Q3 2025 | 21 | 0 | 20.11M | $8.43B | +1 | −2 |
| Q2 2025 | 19 | 0 | 20.17M | $5.79B | n/a | n/a |
| Q1 2025 | 16 | +1 | 10.14M | $3.12B | +1 | n/a |
| Q4 2024 | 15 | 0 | 10.52M | $3.71B | +1 | −1 |
| Q3 2024 | 14 | 0 | 8.99M | $3.22B | n/a | n/a |
| Q2 2024 | 14 | n/a | 8.17M | $2.60B | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (被动) | 5.35M | +0.4% | $2.24B | 0.0% | ▲ Add | 2 | SEC ↗ ×22 |
| 2 | The Vanguard Group ✦ (被动) | 4.42M | -0.7% | $1.85B | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | Renaissance Technologies ✦ | 2.17M | +2.6% | $911.11M | 1.2% | ▲ Add | 6 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (被动) | 1.92M | -11.3% | $805.98M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | Wellington Management ✦ | 1.40M | -3.1% | $586.38M | 0.1% | ▼ Trim | 6 | SEC ↗ ×7 |
| 6 | Geode Capital Management ✦ (被动) | 1.25M | +4.1% | $522.91M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | AQR Capital Management ✦ | 986.48K | -22.5% | $413.54M | 0.3% | ▼ Trim | 6 | SEC ↗ ×4 |
| 8 | JPMorgan Chase ✦ | 495.87K | n/a | $207.88M | 0.0% | n/c | 1 | SEC ↗ ×28 |
| 9 | Morgan Stanley ✦ | 438.80K | n/a | $183.95M | 0.0% | n/c | 1 | SEC ↗ ×12 |
| 10 | T. Rowe Price ✦ | 300.93K | +162.8% | $126.15M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 11 | Citadel Advisors ✦ | 273.98K | +94.3% | $114.86M | 0.1% | ▲ Add | 4 | SEC ↗ ×2 |
| 12 | Millennium Management ✦ | 258.58K | +235.5% | $108.40M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 13 | Fidelity (FMR) ✦ | 250.33K | -41.0% | $104.94M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 14 | Arrowstreet Capital ✦ | 208.53K | -38.5% | $87.42M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 15 | Point72 Asset Management ✦ | 99.78K | 新增 | $41.83M | 0.1% | New | 1 | SEC ↗ |
| 16 | Goldman Sachs Group ✦ | 81.54K | n/a | $34.18M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 17 | Gotham Asset Management ✦ | 80.96K | -9.4% | $33.94M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 64.71K | +199.5% | $27.13M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 19 | Fisher Asset Management ✦ | 23.58K | +26.8% | $9.89M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 20 | Two Sigma Investments ✦ | 16.09K | +82.8% | $6.75M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 21 | Bridgewater Associates ✦ | 16.07K | -91.8% | $6.73M | 0.0% | ▼ Trim | 6 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Point72 Asset Management | $41.83M | 0.1% |
已清仓
| Norges Bank | $136.45M | 曾为 0.0% |
| Marshall Wace | $79.45M | 曾为 0.1% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 844 持有人, 41.22M 股份, $23.10B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Officer, Director · 315 股 · $176,612
Officer, Director · 320 股 · $178,280
Officer, Director · 520 股 · $290,537
Officer, Director · 586 股 · $322,311
Officer, Director · 1.13K 股 · $624,870
Officer, Director · 1.56K 股 · $860,883
Officer, Director · 1.26K 股 · $697,996
Officer, Director · 575 股 · $314,977
Officer, Director · 948 股 · $520,400
Officer, Director · 464 股 · $261,130
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论